Skip to content
Open access

Nivolumab and total neoadjuvant treatment for locally advanced rectal cancer: results of a phase II trial (CA209-8M4).

Nov 2026 · ESMO Open · Vol 11 11, pp. 108617 · 0 citations · 28 references
Medicine

Abstract

Background

CA209-8M4 is a prospective phase II trial evaluating the addition of nivolumab to total neoadjuvant treatment (TNT) in patients with locally advanced rectal cancer (LARC).

Materials And Methods

Patients with LARC (T3-4Nany or TanyN1) up to 12 cm from the anal verge received standard chemoradiation (CRT) followed by chemoimmunotherapy (CIMT): six cycles of standard mFOLFOX6 and nivolumab at 240 mg. We defined a novel primary endpoint, combining pathological complete response (pCR) rate among operated patients and long-term (≥12 months) clinical complete response (cCR) rate for those electing watchful waiting, into a composite endpoint of modified pCR (mpCR) rate.

Results

Between April 2019 and March 2024, 29 patients were enrolled, median age 53 years, 72.4% male; 96.6% of tumors were cT3 or cT4, 69.0% cN+, and 96.6% microsatellite stable. Median distance from the anal verge was 7 cm; 51.7% of patients had grade ≥3 adverse events (AEs) during CIMT, including one fatality (mesenteric inflammation), attributed most likely to CRT's unresolved toxicity. Immune-mediated AEs occurred in four patients (13.8%): grade 3 diabetes mellitus (1) and grade 1 hepatitis (3), including one with asymptomatic hyper/hypothyroidism. Twenty-eight patients (96.6%) are assessable for mpCR: 6 of the 15 operated achieved pCR, and 13 were not operated with cCR ≥12 months, leading to a 67.9% mpCR rate. With a median follow-up of 43.5 months (range 25.0-84.1+), all 28 assessable pts are alive with no evidence of disease. The estimated 3-year disease-free survival and 5-year overall survival rates of the entire group are 93% [95% confidence interval (CI) 84-100] and 97% (95% CI 90-100), respectively.

Conclusions

The addition of nivolumab to standard TNT in LARC seems safe and may enhance its effectiveness, with encouraging mpCR and survival rates. A multicenter randomized trial, further evaluating this strategy, is ongoing.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.